ArticleStem cells international2025
Human Umbilical Cord Mesenchymal Stem Cells Inhibit the Progression of Osteoarthritis by Suppressing NLRP3-Mediated Synovial Inflammation in the Early Stages of the Disease.
Article in Stem cells international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is the leading joint disease that causes joint pain and disability. Despite increasing progress regarding the therapeutic potential of human umbilical cord mesenchymal stem cells (UC-MSCs) for OA, effective strategies for the treatment of OA using UC-MSCs have not yet been developed in clinical practice. Our present study has proven that the early stage in OA rats is the main development stage of nod-like receptor heat protein domain protein 3 (NLRP3)-mediated synovial inflammation. The middle stage in OA rats is the main development stage of chondrocyte apoptosis. The late stage in OA rats is the main development stage of synovial fibrosis. The treatment of UC-MSCs in the early and middle stages of OA significantly reduced cartilage damage in rats, and improved the pathological structure of the knee joint. In comparison, UC-MSCs effectively reduced chondrocyte apoptosis in the early and middle stages of OA rats, but they only effectively reduced NLRP3-mediated synovial inflammation in the early stages of OA rats. Experiments in vitro showed that UC-MSCs could inhibit NLRP3-mediated pyroptosis of rat primary synovial cells (Rat-scs). In conclusion, our findings suggest that UC-MSCs exert therapeutic effects on OA, at least in part, through inhibiting NLRP3-mediated synovial inflammation in the early stage of OA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.